Corbus Pharmaceuticals Holdings Inc (CRBP) FinancialsCRBPCorbus Pharmaceuticals Holdings Inc

Evaluating the bottom line, Corbus Pharmaceuticals Holdings, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -95.58%, provide a clear picture of how effectively CRBP converts its operational activities into shareholder value.

In the context of the broader market, CRBP competes directly with industry leaders such as ATRA and TNYA. With a market capitalization of $59.37M, it holds a significant position in the sector. When comparing efficiency, CRBP's gross margin of N/A stands against ATRA's 69.68% and TNYA's N/A. Such benchmarking helps identify whether Corbus Pharmaceuticals Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Corbus Pharmaceuticals has shown poor financial performance with a net income of -$35,037,000 in Q2 2026 and a gross profit of -$50,000 in the same quarter. The company has a current ratio of 5.71, indicating some liquidity but overall negative profitability metrics.